HLN vs. LMAT: Which Stock Is the Better Value Option? Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
HLN vs. LMAT: Which Stock Should Value Investors Buy Now? Acadia Pharmaceuticals ACAD is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide).
Haleon to quieten 'noise' with latest update, broker suggests Haleon PLC (LSE:HLN, NYSE:HLN) first half/second quarter results on 1 August should be the last of ‘noise and volatility' this year, suggests broker Jefferies. From here on, it should be a normalised base of sales says the US bank, which expects volumes and product mix to underline it can be a 4-6% organic growth business.
Deutsche Bank lowers Haleon shares target amid forecast revisions https://www.investing.com/news/company-news/deutsche-bank-lowers-haleon-shares-target-amid-forecast-revisions-93CH-3511187
What next for Haleon shares? Analysts say consumer spin-off is undervalued Berenberg also argues that the shares are trading at a tempting 17 per cent discount to other personal care products groups.
Dr. Reddy''s share maintains buy rating on Haleon acquisition https://www.investing.com/news/company-news/dr-reddys-share-maintains-buy-rating-on-haleon-acquisition-93CH-3504178
POPULAR SHARES: Analysts at Berenberg keen on Haleon Berenberg also argues that the shares are trading at a tempting 17 per cent discount to other personal care products groups.
Dr. Reddy''s to Acquire Haleon''s Nicotine Addiction Drug Dr. Reddy''s Laboratories (NYSE: RDY ) has announced a definitive agreement with Haleon plc (NYSE: HLN ) to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category, excluding the United States. The impending acquisition will add Nicotinell, Haleon''s leading NRT brand with a presence in more than 30 countries across the EU, Asia (including Japan) and Latin America, to RDY''s portfolio of global consumer healthcare over-the-counter (OTC) drugs. It also encompasses local market-leading brands, such as Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada. The acquisition will cover all product formats, including lozenge, patch, gum and pipeline products, in all applicable global markets outside the United States. The strategic move is set to further strengthen Dr. Reddy''s OTC business. Please note that Haleon''s Nicotinell is the world''s second-largest brand in the NRT category, excluding the United States. It holds either the first or second position in 14 out of the top 17 global markets, with its lozenge/mini lozenge format being the top choice globally.
Dr Reddy’s inks pact with Haleon plc to acquire its NRT portfolio for GBP 500M The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States, it said.
Haleon to sell nicotine replacement therapy business outside US for $633 mln British consumer healthcare company Haleon said on Wednesday it would sell its nicotine replacement therapy business outside the United States to a unit of India's Dr. Reddy's for 500 million pounds ($632.55 million).